Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | GRPR | P30550 | 1/20 | 0.38 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.37 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836059 | 0.85 | CALCRL (0.46) | CALCRLKEAP1BACE1CTSDMAPK8 | |
| SCHEMBL30601031 | 0.82 | CALCRL (0.50) | CALCRLKEAP1BACE1CTSDGRPR | |
| SCHEMBL31122253 | 0.82 | CALCRL (0.45) | CALCRLKEAP1MAPK8MAPK9MAPK10 | |
| SCHEMBL29914541 | 0.82 | MEN1 (0.42) | CALCRLBACE1CTSD | |
| SCHEMBL29416180 | 0.81 | CALCRL (0.45) | CALCRLKEAP1BACE1CTSDMAPK8 | |
| SCHEMBL29308375 | 0.81 | KEAP1 (0.38) | CALCRLKEAP1MAPK8MAPK9MAPK10 | |
| SCHEMBL31461867 | 0.80 | KEAP1 (0.46) | KEAP1BACE1CTSDMAPK8MAPK9 | |
| SCHEMBL38657878 | 0.80 | CALCRL (0.43) | CALCRLKEAP1BACE1CTSDMAPK8 | |
| SCHEMBL30930183 | 0.79 | MEN1 (0.42) | CALCRLBACE1CTSDMAPK8MAPK9 | |
| SCHEMBL30112831 | 0.79 | DPP7 (0.41) | CALCRLKEAP1CDYL2CDYL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705465-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| EP-4676497-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CELL DEATH INDUCING DFFA LIKE EFFECTOR B (CIDEB) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| EP-4638742-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-29 | — | — | EP | claimed |
| EP-4630556-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING 3 (PNPLA3) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | claimed |
| EP-4592390-A1 | SPECIFICALLY MODIFIED RNAI REAGENT AND COMPOSITION | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-07-30 | — | — | EP | claimed |
| CN-117723887-B | Fusion ranging method based on multi-band identification | 北京四方继保工程技术有限公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2025077711-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-04-17 | — | — | WO | claimed |
| WO-2025077806-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-04-17 | — | — | WO | claimed |
| WO-2024240058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-11-28 | — | — | WO | claimed |
| WO-2024188164-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CELL DEATH INDUCING DFFA LIKE EFFECTOR B (CIDEB) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-09-19 | — | — | WO | claimed |
| CN-113166759-B | Chemically modified RNAi constructs and uses thereof | 美国安进公司 | 2024-07-12 | — | — | CN | claimed |
| WO-2024131916-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | WO | claimed |
| WO-2024120412-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING 3 (PNPLA3) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-06-13 | — | — | WO | claimed |
| WO-2023044567-A1 | COMPOSITIONS COMPRISING A SATURATED OR UNSATURATED ALIPHATIC ACID AND A NON-IONIC SURFACTANT FOR ENHANCING PENETRATION OF PESTICIDE COMPONENTS | TERRAMERA, INC. (CA) | 2023-03-30 | — | — | WO | claimed |
| EP-4747385-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COMPLEMENT COMPONENT 3 (C3) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747381-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PD-L1 | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4735600-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| CN-114621888-A | Lactobacillus casei with intestinal immunity disorder regulation function and application thereof | 青岛蔚蓝生物股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-111088213-B | Method for inducing stem cells to gradually differentiate to form keratinocytes and keratinocytes | 澳门大学 | 2022-04-08 | — | — | CN | disclosed |
| US-11280643-B2 | Monitoring humidity measurement system and monitoring humidity measurement method | NEUBREX CO., LTD. (JP) | 2022-03-22 | — | — | US | disclosed |